How will health issues affect voter choices? What will happen if President Donald Trump is reelected or the White House goes to Joe Biden? In this special election preview episode, Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.
Democrats on the House Oversight Committee released a damning investigation Wednesday of drug company pricing tactics and profits, as two days of hearings with testimony from pharmaceutical industry CEOs begin.
The death of Supreme Court Justice Ruth Bader Ginsburg is giving new life to the latest constitutional challenge to the Affordable Care Act. It also places anti-abortion activists on the cusp of a court majority large enough to ensure the rollback of the right to abortion and, possibly, some types of birth control. Meanwhile, Health and Human Services Secretary Alex Azar tries to centralize power at the sprawling department plagued by miscommunications and scandals. Anna Edney of Bloomberg News, Kimberly Leonard of Business Insider and Mary Ellen McIntire of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Plus, Rovner interviews KHN’s Sarah Jane Tribble about her new podcast, “Where It Hurts,” debuting Sept. 29.
While insulin is the poster child for outrageous prescription costs, patients are paying ever more to treat depression, asthma, HIV, cholesterol and more. And the pandemic has overtaken efforts to force the issue in Congress.
The Trump administration is primed to approve a plan designed to help lower costs of some prescription drugs by allowing states to import them from Canada. The announcement could come before Election Day, and Florida appears to be in line to go first.
President Donald Trump this week issued a prescription drug pricing order unlikely to lower drug prices, and he contradicted comments by his director of the Centers for Disease Control and Prevention on the need for mask-wearing and predictions for vaccine availability. Meanwhile, scandals erupted at the CDC, the Centers for Medicare & Medicaid Services and the Food and Drug Administration. And the number of people without health insurance grew in 2019, reported the Census Bureau, even while the economy soared. Alice Miranda Ollstein of Politico, Tami Luhby of CNN and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss this and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
California could become the first state to develop its own line of generic drugs under a bill approved Monday by the legislature. The measure heads to Gov. Gavin Newsom for consideration.
During his Monday speech at the Republican National Convention, President Donald Trump pointed to his two of his recent executive orders as likely to lead to big reductions in prescription drug costs.
President Donald Trump’s sobering view of COVID-19 didn’t last long – this week, he was back to pushing hydroxychloroquine, a drug that has been shown not to work in treating the virus. Meanwhile, Republicans on Capitol Hill are still scrambling to agree among themselves and with the White House on the next coronavirus relief bill, as both a moratorium on evictions and extra unemployment payments expire. And the debate over drug prices, which was going to be one of the biggest health issues of this election year, makes a brief appearance. Alice Miranda Ollstein of Politico, Mary Ellen McIntire of CQ Roll Call and Anna Edney of Bloomberg News join KHN’s Julie Rovner to discuss this and more. Also, Rovner interviews KHN’s Markian Hawryluk, who wrote the latest KHN-NPR “Bill of the Month” story about a surprise bill from a surprise surgical assistant.
A rule finalized this spring by the Trump administration permits employers and insurers not to apply drug company copayment assistance toward enrollees’ deductibles and out-of-pocket maximums for any drug.
